Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Alabama at Birmingham
Global Coalition for Adaptive Research
NRG Oncology
Mayo Clinic
University of California, San Francisco
NRG Oncology
Case Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Sapience Therapeutics
Mayo Clinic
BPGbio
NRG Oncology
M.D. Anderson Cancer Center
Northwestern University
National Institutes of Health Clinical Center (CC)
Northwestern University
Karolinska Institutet
Hopital Foch
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
Mayo Clinic
Northwestern University
M.D. Anderson Cancer Center
Thomas Jefferson University
Washington University School of Medicine
Ann & Robert H Lurie Children's Hospital of Chicago
Candel Therapeutics, Inc.
BeiGene
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)
Academic and Community Cancer Research United
Northwell Health
Basilea Pharmaceutica
Massachusetts General Hospital
National Cancer Institute (NCI)
Northwestern University
Candel Therapeutics, Inc.
Canadian Cancer Trials Group
AbbVie
Children's Oncology Group
St. Jude Children's Research Hospital
EpicentRx, Inc.
Spectrum Pharmaceuticals, Inc
Jonsson Comprehensive Cancer Center
AbbVie
Peking Union Medical College Hospital